|Bid||133.05 x 900|
|Ask||141.22 x 800|
|Day's range||135.19 - 136.24|
|52-week range||119.59 - 158.34|
|Beta (5Y monthly)||0.90|
|PE ratio (TTM)||20.25|
|Earnings date||31 Jan 2024 - 05 Feb 2024|
|Forward dividend & yield||2.84 (2.09%)|
|Ex-dividend date||16 Jan 2024|
|1y target est||142.79|
Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that it has been awarded a contract by the United States Centers for Disease Control and Prevention (CDC) designed to assess the burden of hepatitis C virus (HCV) in the United States